World News

The deal gives Kyowa Kirin access to Knight’s pan-American commercial infrastructure while allowing Knight to add a targeted oncology therapy to its portfolio.

Sanofi will pay Regeneron US$1 billion upfront, with development, regulatory, and commercial milestones potentially adding another US$ 7 billion.

The Mainz-based biopharmaceutical company said the closures will affect about 1,800 employees at sites in Tübingen, Marburg and Idar-Oberstein.

The financing comes as NorthStar expands its role in the radiopharmaceutical supply chain, particularly for actinium 225 (Ac 225), an alpha-emitting radioisotope used to develop targeted cancer therapies.

Profluent will conduct the computational design work using its Profluent Protein Atlas, a dataset containing more than 115 billion unique protein sequences.

OBIO has selected six companies for the 2026 intake, spanning artificial intelligence, biotechnology, diagnostics, medical devices, and therapeutics.

Seven countries, which include Angola, Bangladesh, the Democratic Republic of the Congo, Nigeria, South Sudan, Sudan and Yemen, accounted for about 90% of reported cases and deaths.

D-dimer testing measures fragments produced when blood clots break down and can help assess patients with increased clotting activity.

TLB 33 is a human immunoglobulin G1 monoclonal antibody designed to bind to and neutralise interleukin 33, an immune signalling protein.

The Danish pharmaceutical company will receive exclusive rights to develop, manufacture and commercialise HRS-1596 outside mainland China, Hong Kong, Macau and Taiwan.